Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors

Trial Profile

A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TTI 621 (Primary) ; Nivolumab; Rituximab
  • Indications Acute myeloid leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Haematological malignancies; Hodgkin's disease; Lymphoma; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Peripheral T-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Small cell lung cancer; Solid tumours; T-cell lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Trillium Therapeutics Inc
  • Most Recent Events

    • 22 Oct 2019 According to Trillium Therapeutics media release, The 0.7 mg/kg dose cohort in this study has been completed and enrollment in the 1.0 mg/kg cohort is beginning.
    • 10 May 2019 Planned End Date changed from 1 Jun 2020 to 1 Jun 2021.
    • 10 May 2019 Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top